TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum StockStory
Covered in this story
Analyst targets on Thermo Fisher Scientific
- Morgan Stanley: $663 → $730 by Oct 2027 · Overweight via ad-hoc-news.de
- UBS: $606 → $730 by Sep 2027 · Buy via Investing.com
- Morgan Stanley: $560 → $650 by Jul 2027 · Overweight via GuruFocus
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $TMO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Thermo Fisher Scientific →Dalsna Finance is currently tracking 46 stories mentioning Thermo Fisher Scientific, the earliest published 9 Jul 2026.
Summary aggregated from StockStory's public RSS feed. The full reporting belongs to StockStory — please read it on their site.